MX2018008413A - Virus oncolitico modificado. - Google Patents

Virus oncolitico modificado.

Info

Publication number
MX2018008413A
MX2018008413A MX2018008413A MX2018008413A MX2018008413A MX 2018008413 A MX2018008413 A MX 2018008413A MX 2018008413 A MX2018008413 A MX 2018008413A MX 2018008413 A MX2018008413 A MX 2018008413A MX 2018008413 A MX2018008413 A MX 2018008413A
Authority
MX
Mexico
Prior art keywords
viurs
modified oncolytic
encoding gene
oncolytic
modified
Prior art date
Application number
MX2018008413A
Other languages
English (en)
Inventor
Coffin Robert
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57796748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008413(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1600382.4A external-priority patent/GB201600382D0/en
Priority claimed from GBGB1600381.6A external-priority patent/GB201600381D0/en
Priority claimed from GBGB1600380.8A external-priority patent/GB201600380D0/en
Application filed by Replimune Ltd filed Critical Replimune Ltd
Publication of MX2018008413A publication Critical patent/MX2018008413A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un virus oncolítico que comprende: (i) un gen que codifica una proteína fusogénica; y (ii) un gen que codifica una molécula inmunoestimulante.
MX2018008413A 2016-01-08 2017-01-09 Virus oncolitico modificado. MX2018008413A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1600382.4A GB201600382D0 (en) 2016-01-08 2016-01-08 Engineered virus
GBGB1600381.6A GB201600381D0 (en) 2016-01-08 2016-01-08 Virus strain
GBGB1600380.8A GB201600380D0 (en) 2016-01-08 2016-01-08 Modified virus
PCT/GB2017/050036 WO2017118864A1 (en) 2016-01-08 2017-01-09 Modified oncolytic viurs

Publications (1)

Publication Number Publication Date
MX2018008413A true MX2018008413A (es) 2019-02-20

Family

ID=57796748

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008413A MX2018008413A (es) 2016-01-08 2017-01-09 Virus oncolitico modificado.

Country Status (15)

Country Link
US (11) US10612005B2 (es)
EP (7) EP3778881A1 (es)
JP (6) JP7038065B2 (es)
KR (1) KR20180103956A (es)
CN (3) CN109312309B (es)
AU (2) AU2017205216B2 (es)
BR (1) BR112018013930A2 (es)
CA (3) CA3011009A1 (es)
DK (3) DK3400293T4 (es)
ES (3) ES2831080T5 (es)
HK (3) HK1257074A1 (es)
IL (2) IL260480B (es)
MX (1) MX2018008413A (es)
SG (2) SG11201805835WA (es)
WO (4) WO2017118867A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568779A1 (en) * 2000-01-21 2005-08-31 BioVex Limited HSV strains for the oncolytic treatment of cancer
MY147379A (en) 2005-12-02 2012-11-30 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
EP2158668A4 (en) 2007-05-31 2017-07-19 Krishnan Ramu Switched reluctance machines with minimum stator core
SG11201507412SA (en) 2013-03-14 2015-10-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
ES2831080T5 (es) * 2016-01-08 2023-10-30 Replimune Ltd Virus oncolítico modificado
SG11201806134SA (en) 2016-01-27 2018-08-30 Oncorus Inc Oncolytic viral vectors and uses thereof
WO2017181420A1 (en) * 2016-04-22 2017-10-26 Immuno Vir Co., Limited CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
KR20190035714A (ko) * 2016-06-30 2019-04-03 온코루스, 인크. 치료 폴리펩티드의 위형된 종양용해성 바이러스 전달
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
MA56289B1 (fr) 2017-08-03 2022-04-29 Amgen Inc Mutéines d'interleukine-21 et méthodes de traitement
IL272512B (en) 2017-09-08 2022-07-01 Amgen Inc kras g12c inhibitors and methods of using them
CN109554353B (zh) * 2017-09-26 2021-08-06 杭州康万达医药科技有限公司 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
CA3082117A1 (en) * 2017-11-13 2019-05-16 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
JP2021508477A (ja) * 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
MA51631A (fr) 2018-01-12 2020-11-18 Amgen Inc Anticorps anti-pd1 et méthodes de traitement
EP3743095A1 (en) * 2018-01-26 2020-12-02 Celldex Therapeutics, Inc. Methods of treating cancer with dendritic cell mobilizing agents
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN108635380A (zh) * 2018-04-13 2018-10-12 北京唯源立康生物科技有限公司 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用
EP3810191A1 (en) * 2018-06-21 2021-04-28 Replimune Limited Treatment using oncolytic virus
US20210261649A1 (en) * 2018-06-29 2021-08-26 Krystal Biotech, Inc, Compositions and methods for antibody delivery
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
AU2019351255A1 (en) 2018-09-26 2021-04-29 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
EP3902529A1 (en) 2018-12-27 2021-11-03 Amgen Inc. Lyophilized virus formulations
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
CN113439123A (zh) 2019-03-05 2021-09-24 安进公司 溶瘤病毒用于治疗癌症的用途
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
KR20220044310A (ko) * 2019-08-05 2022-04-07 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 악성 종양을 치료하기 위한 병용약, 악성 종양을 치료하기 위한 의약 조성물 및 악성 종양 치료용 의약 조성물
US11951141B2 (en) * 2019-11-06 2024-04-09 Memgen, Inc. Replication-enhanced oncolytic adenoviruses
EP4112724A4 (en) * 2020-03-05 2023-08-23 Beijing Wellgene Biotech Co., Ltd. HERPES SIMPLEX VIRUS AND ITS USE
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
WO2021193081A1 (ja) * 2020-03-23 2021-09-30 国立大学法人東海国立大学機構 １型単純ヘルペスウイルス
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112941039A (zh) * 2021-02-01 2021-06-11 南京大学 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用
DE102022104146A1 (de) 2021-03-19 2022-09-22 Yamada Manufacturing Co., Ltd. Lenkvorrichtung
WO2022245808A1 (en) * 2021-05-18 2022-11-24 The Penn State Research Foundation Oncolytic virus based cancer therapy
CN113583979B (zh) * 2021-08-03 2022-11-22 杭州荣谷生物科技有限公司 一种重组溶瘤痘苗病毒、制备方法及其用途
WO2024055022A2 (en) * 2022-09-08 2024-03-14 Virogin Biotech Canada Ltd Oncolytic virus expressing an immune cell engager for tumor targeting

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
EP0675961B1 (en) 1992-03-31 2002-11-27 Arch Development Corporation Treatment of tumorigenic disease with a modified HSV
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
EP0862445B2 (en) 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
MXPA02004736A (es) 1999-11-12 2003-01-28 Oncolytics Biotech Inc Virus para el tratamiento de trastornos proliferativos celulares.
EP1568779A1 (en) 2000-01-21 2005-08-31 BioVex Limited HSV strains for the oncolytic treatment of cancer
US7749745B2 (en) 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
JP2008518902A (ja) 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
US9866961B2 (en) 2004-12-01 2018-01-09 Todd Beauchamp Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers
BRPI0608815B1 (pt) 2005-03-08 2021-10-13 Pfizer Products Inc Composições de anticorpo anti-ctla-4
WO2006121810A2 (en) 2005-05-06 2006-11-16 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
CA2613310C (en) 2005-06-23 2014-06-17 Baylor College Of Medicine Use of mutant herpes simplex virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
CN102575227A (zh) 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011063309A1 (en) 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
AU2011306845C1 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
PT2753355T (pt) * 2011-09-08 2019-02-01 Univ New York Vírus herpes simplex oncolítico e suas utilizações terapêuticas
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
SG11201404313YA (en) 2012-01-25 2014-10-30 Dnatrix Inc Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR20150038066A (ko) 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
AU2013308595C1 (en) 2012-08-30 2019-01-17 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
SG11201507412SA (en) 2013-03-14 2015-10-29 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
EA039404B1 (ru) 2013-09-03 2022-01-24 Медиммун Лимитед Аттенуированный вирус ньюкаслской болезни (ndv) штамма 73т для лечения неоплазии, способ селективного цитолиза опухолевых клеток и способ индуцирования регресса опухоли с его использованием
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
JP2016540505A (ja) * 2013-11-22 2016-12-28 ディーエヌエートリックス インコーポレイテッド アデノウイルス発現免疫細胞刺激受容体アゴニスト
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US10555981B2 (en) 2014-07-16 2020-02-11 Transgene S.A. Oncolytic virus for expression of immune checkpoint modulators
US10765710B2 (en) 2014-07-16 2020-09-08 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators
US20160040186A1 (en) 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10525557B2 (en) 2015-01-23 2020-01-07 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
ES2831080T5 (es) * 2016-01-08 2023-10-30 Replimune Ltd Virus oncolítico modificado
WO2017181420A1 (en) 2016-04-22 2017-10-26 Immuno Vir Co., Limited CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3810191A1 (en) 2018-06-21 2021-04-28 Replimune Limited Treatment using oncolytic virus

Also Published As

Publication number Publication date
JP2022002531A (ja) 2022-01-11
ES2841300T5 (es) 2024-08-06
DK3400293T4 (da) 2023-08-28
CN109153977A (zh) 2019-01-04
US12049647B2 (en) 2024-07-30
US10570377B2 (en) 2020-02-25
EP3400293B2 (en) 2023-07-12
US20190032024A1 (en) 2019-01-31
EP3400291A1 (en) 2018-11-14
DK3400291T3 (da) 2020-11-30
US10612005B2 (en) 2020-04-07
SG10202108724YA (en) 2021-09-29
EP3400293A1 (en) 2018-11-14
JP7295192B2 (ja) 2023-06-20
DK3400291T4 (da) 2024-04-02
US20230212531A1 (en) 2023-07-06
JP2019501671A (ja) 2019-01-24
EP3400292B1 (en) 2020-08-26
IL260480B (en) 2021-05-31
US20230130992A1 (en) 2023-04-27
ES2831080T3 (es) 2021-06-07
CN109312309B (zh) 2024-04-02
US20200208122A1 (en) 2020-07-02
US11473063B2 (en) 2022-10-18
IL282985B (en) 2022-04-01
DK3400293T3 (da) 2020-10-19
EP4219696A3 (en) 2023-09-27
CA3010987A1 (en) 2017-07-13
HK1257480A1 (zh) 2019-10-18
US20200199542A1 (en) 2020-06-25
US20240018488A1 (en) 2024-01-18
EP3400290B1 (en) 2023-04-05
IL282985A (en) 2021-06-30
US20210254019A1 (en) 2021-08-19
US20230203453A1 (en) 2023-06-29
CN109153977B (zh) 2022-11-01
KR20180103956A (ko) 2018-09-19
US12024724B2 (en) 2024-07-02
WO2017118867A1 (en) 2017-07-13
ES2841300T3 (es) 2021-07-08
CN109312309A (zh) 2019-02-05
CN109415703A (zh) 2019-03-01
EP3400290A1 (en) 2018-11-14
JP2022078225A (ja) 2022-05-24
EP4219696A2 (en) 2023-08-02
ES2831080T5 (es) 2023-10-30
US10626377B2 (en) 2020-04-21
EP3400293B1 (en) 2020-09-16
AU2017205216A1 (en) 2018-08-09
US20190022157A1 (en) 2019-01-24
WO2017118865A1 (en) 2017-07-13
EP3400291B1 (en) 2020-11-04
SG11201805835WA (en) 2018-08-30
JP7038664B2 (ja) 2022-03-18
WO2017118864A1 (en) 2017-07-13
DK3400290T3 (da) 2023-05-01
JP2019501670A (ja) 2019-01-24
EP3778881A1 (en) 2021-02-17
CA3011004A1 (en) 2017-07-13
HK1257224A1 (zh) 2019-10-18
JP7038065B2 (ja) 2022-03-17
AU2017205216B2 (en) 2022-11-24
US11427810B2 (en) 2022-08-30
JP2023113885A (ja) 2023-08-16
BR112018013930A2 (pt) 2018-12-11
EP3805376A1 (en) 2021-04-14
US10947513B2 (en) 2021-03-16
EP3400291B2 (en) 2024-02-28
JP6959258B2 (ja) 2021-11-02
US20190015466A1 (en) 2019-01-17
ES2943150T3 (es) 2023-06-09
AU2022279486A1 (en) 2023-02-02
US20190040366A1 (en) 2019-02-07
CA3011009A1 (en) 2017-07-13
JP2019500909A (ja) 2019-01-17
EP3400292A1 (en) 2018-11-14
WO2017118866A1 (en) 2017-07-13
HK1257074A1 (zh) 2019-10-11

Similar Documents

Publication Publication Date Title
MX2018008413A (es) Virus oncolitico modificado.
PH12018500855A1 (en) Herpes simplex virus vaccine
EP4403229A3 (en) Expression of pten-long with oncolytic viruses
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX2017009538A (es) Antigenos de citomegalovirus y su uso.
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
SA515360198B1 (ar) لقاحات غمس الوحدات الفرعية للسمك
MX2019011272A (es) Composiciones y metodos para inmunooncologia.
MY191539A (en) Streptococcal vaccine
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
AR119653A1 (es) Cepa cjlp475 de lactobacillus plantarum que tiene efectos antivirales e inmunomoduladores y una composición que comprende la misma
MX2021010808A (es) Ácido ribonucleico replicón-nanopartículas sinteticas oncolítico y sintético y usos para inmunoterapia de cáncer.
WO2018138681A9 (en) Hemagglutinin-specific antibodies and uses thereof
MX363464B (es) Vacunas contra influenza h5.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
EP4008343A3 (en) Methods and compositions related to increased viral production
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MX2016009747A (es) Vacunas contra el reovirus aviar.
BR112017024786A2 (pt) virus oncolíticos recombinantes e usos dos mesmos
WO2019012481A3 (en) G-QUADRUPLEXES DIVIDED FOR CAPTURE AND DETECTION OF NUCLEIC ACIDS
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
EP3490595A4 (en) OPTIMIZED ZIKAVIRUS ENVELOPES AND EXPRESSION THEREOF